Phage therapy: awakening a sleeping giant
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
For a century, bacterial viruses called bacteriophages have been exploited as natural antibacterial agents. However, their medicinal potential has not yet been exploited due to readily available and effective antibiotics. After years of extensive use, both properly and improperly, antibiotic-resistant bacteria are becoming more prominent and represent a worldwide public health threat. Most importantly, new antibiotics are not progressing at the same rate as the emergence of resistance. The therapeutic modality of bacteriophages, called phage therapy, offers a clinical option to combat bacteria associated with diseases. Here, we discuss traditional phage therapy approaches, as well as how synthetic biology has allowed for the creation of designer phages for new clinical applications. To implement these technologies, several key aspects and challenges still need to be addressed, such as narrow spectrum, safety, and bacterial resistance. We will summarize our current understanding of how phage treatment elicits mammalian host immune responses, as well bacterial phage resistance development, and the potential impact each will have on phage therapy effectiveness. We conclude by discussing the need for a paradigm shift on how phage therapy strategies are developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Costelloe, C., Metcalfe, C., Lovering, A., Mant, D., & Hay, A. D. (2010) · BMJ · doi:10.1136/bmj.c2096 · Cited by 1,981
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986
Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases
Citorik, R. J., Mimee, M., & Lu, T. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.3011 · Cited by 808
Jordan, T. C., Burnett, S. H., Carson, S., Caruso, S. M., Clase, K., DeJong, R. J., Dennehy, J. J., Denver, D. R., Dunbar, D., Elgin, S. C. R., et al. (2014) · mBio · doi:10.1128/mbio.01051-13 · Cited by 509
Mammalian Host-Versus-Phage immune response determines phage fate in vivo
Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., Lecion, D., Kaźmierczak, Z., Beta, W., Majewska, J., Harhala, M., et al. (2015) · Scientific Reports · doi:10.1038/srep14802 · Cited by 302
Phenotypic Resistance and the Dynamics of Bacterial Escape from Phage Control
Bull, J. J., Vegge, C. S., Schmerer, M., Chaudhry, W. N., & Levin, B. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094690 · Cited by 123
Cited by
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Oechslin, F. (2018) · Viruses · doi:10.3390/v10070351 · Cited by 594
Roach, D. R., Leung, C. Y., Henry, M., Morello, E., Singh, D., Di Santo, J. P., Weitz, J. S., & Debarbieux, L. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.06.018 · Cited by 484
Self-citationMechanisms and clinical importance of bacteriophage resistance
Egido, J. E., Costa, A. R., Aparicio-Maldonado, C., Haas, P.-J., & Brouns, S. J. J. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab048 · Cited by 325
Contemporary Phage Biology: From Classic Models to New Insights
Ofir, G., & Sorek, R. (2018) · Cell · doi:10.1016/j.cell.2017.10.045 · Cited by 293
Standardized bacteriophage purification for personalized phage therapy
Luong, T., Salabarria, A.-C., Edwards, R. A., & Roach, D. R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0346-0 · Cited by 274
Self-citation
Metadata
- Authors
- Roach, D. R., & Debarbieux, L.
- Venue
- Emerging Topics in Life Sciences
- Publisher
- Portland Press Ltd.
- Published
- 2017-04-21
- Volume
- 1
- Issue
- 1
- Pages
- 93-103
- ISSN
- 2397-8554 (ISSN-L)
- 2397-8562
- OpenAlex
- W2606644876
- Cited by
- 116
- References
- 7
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phage therapy: awakening a sleeping giant. https://app.cochat.ai/papers/10.1042/etls20170002
- The paper
- Roach, D. R., & Debarbieux, L. (2017). Phage therapy: awakening a sleeping giant. Emerging Topics in Life Sciences. https://doi.org/10.1042/etls20170002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.